TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06718556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Client-centered
Description: The client-centered (CC) intervention procedure for individuals with schizophrenia was created using literature and the intervention procedure is presented below:~1. Active Communication and Evaluation~2. Daily Routine, Roles, and Occupational Performance~3. Strengths and Barriers~4. Intervention Program Development~5. Implementation of the intervention program~6. Feedback and Revision:
Study: NCT06715631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hands-free exoskeleton
Description: Before the simulated-use test, the SCI user and his/her companion must attend five training sessions provided by a Wandercraft certified trainer. Training will be composed by a theoretical part including presentation and description of the personal exoskeleton and its use modes and a hands-on practice. Each session lasts between 1 to 2 hours, varying according to the user's learning pace and tolerance. The training program is representative of the intended training for the end product.
Study: NCT06716892

Intervention type: DEVICE
Intervention: Multispectral Optoacoustic Tomography (MSOT)
Description: Non-invasive transcutaneous MSOT imaging of muscle and subcutaneos regions.

Intervention type: DEVICE
Intervention: Multispectral Optoacoustic Tomography (MSOT)
Description: Non-invasive transcutaneous MSOT imaging of muscle and subcutaneos regions.
Study: NCT06712342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Exercise Training
Description: This group will receive neuromuscular exercise training with 60-75 minute sessions per day, 2 days a week, for 8 weeks.~Warm-up Program - 5 minutes Postural Control-Weight Transfer - 10-15 minutes Strength Training - 30-35 minutes Proprioception - Coordination - Reaction Speed 10-15 minutes Cool-down Program - 5 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Exercise Training
Description: This group will be given traditional strength exercise training consisting of 60-75 minute sessions per day, 2 days per week for 8 weeks.~Warm-up Program - 5 minutes Strength Training - 30-35 minutes Manuel Dexterity - 15-20 minutes Cool-down Program - 5 minutes
Study: NCT06715033

Intervention type: DIAGNOSTIC_TEST
Intervention: y balance and SLS
Description: for assessment of static and dynamic balance

Intervention type: DIAGNOSTIC_TEST
Intervention: y balance and SLS
Description: for assessment of static and dynamic balance
Study: NCT04666792

Intervention type: DRUG
Group type: OTHER
Intervention: PrEP
Description: A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya and the United States. The World Health Organization (WHO) recommends TDF-containing medications as PrEP, which includes TDF combined with FTC as well as potentially TDF alone and TDF combined with lamivudine (or 3TC, a medication closely related to FTC). Any TDF-containing medications that align with WHO and Kenya national guidelines for PrEP will be used. PrEP medication will come from clinic stocks.
Study: NCT05124795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMU-935
Description: IMU-935 capsules
Study: NCT05418075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: If the families agree to participate in the study, they are randomly assigned to a treatment group. In each of the three groups, they are treated with FBT in a weekly session. In the two comparison groups, Hometreatment or MBSR are offered in addition to FBT, with two consultations per week in each case.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: If the families agree to participate in the study, they are randomly assigned to a treatment group. In each of the three groups, they are treated with FBT in a weekly session. In the two comparison groups, Hometreatment or MBSR are offered in addition to FBT, with two consultations per week in each case.
Study: NCT03902652

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention (21% oxygen during CC+SI)
Description: Infants randomized into the 21% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.~If heart rate is \>60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains \<60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains \<60/min continue with CC+SI.~During CC+SI the clinical team will only use 21% oxygen.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention (100% oxygen during CC+SI)
Description: Infants randomized into the 100% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.~If heart rate is \>60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains \<60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains \<60/min continue with CC+SI.~During CC+SI the clinical team will only use 100% oxygen.
Study: NCT05991596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychodramatic psychotherapy
Description: The psychodramatic psychotherapy will include a total of 14 meetings during a 6 months period and they will be held in presence (or remotely in case of COVID-19 government restrictions) as follows:~* 1 individual motivational interview;~* 1 weekly group session lasting 2 hours for 1 month (total 4 meetings);~* 1 group session every 15 days lasting 2 hours, for 5 months (total 10 meetings).~Patients will also receive the pharmacological treatment usually recommended for vitiligo.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help activities
Description: The self-help activities will include:~* 1 individual motivational interview;~* 1 weekly, 2 hours group meeting, for 1 month (total 4 meetings);~* 1 group meeting lasting 2 hours every 15 days, for 5 months (total 10 meetings).~Patients will also receive pharmacological treatment usually recommended for vitiligo.
Study: NCT04958135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acoramidis
Description: Film-coated immediate release oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acoramidis
Description: Film-coated immediate release oral tablet.
Study: NCT05657704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The patients in experimental group will be genotyped before surgery and treatment will be prescribed according to the CYP2D6 phenotype
Description: Treatment will be prescribed according to the CYP2D6 phenotype. Normal Metabolizers (NM): Tramadol 100 mg every 8 hour; Ultrarapid Metabolizers (UM): Tramadol 50 mg every 8 hours Intermediate and poor metabolizers (IM/PM): dexketoprofen 25 mg every 8 hours
Study: NCT04912115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine is an FDA-approved N-methyl-D-aspartate (NMDA) receptor-modulating drug pharmacologically classified as an NMDA receptor antagonist (also noted to be a weak opioid receptor agonist).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam is a benzodiazepine used for anesthesia, procedural sedation, trouble sleeping, and severe agitation.
Study: NCT04470024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: agonistic antihuman GITR mAb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCMGA00012
Description: humanized, hinge-stabilized, IgG4κ mAb that recognized human PD-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCMGA00012
Description: humanized, hinge-stabilized, IgG4κ mAb that recognized human PD-1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPV-001
Description: autophagosome cancer vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPV-001
Description: autophagosome cancer vaccine
Study: NCT04954196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg
Description: HRT administration: On Day 1 of the cycle, HRT is planned in accordance with the department's standard practice.~* The frozen embryo transfer will be performed 6 days after progesterone initiation.~* The HRT will be maintained until the pregnancy test is performed: If the test is positive,HRT will be continued for up to 12 weeks of amenorrhea at the same doses and then gradually stopped. If the test is negative,HRT will be stopped gradually~Amlodipine administration: On the day of the first monitoring Dm (corresponding to D13 D16 of the cycle), a single per os dose of amlodipine 5 mg is taken at night, neither the patient nor the investigator knows what drug is the patient getting. Monitoring is systematically performed the next morning.The treatment will be maintained until the pregnancy test is performed then if the test is positive, the treatment will be maintained for a total duration of 7 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: HRT administration: On Day 1 of the cycle, HRT is planned in accordance with the department's standard practice.~* The frozen embryo transfer will be performed 6 days after progesterone initiation.~* The HRT will be maintained until the pregnancy test is performed: If the test is positive, HRT will be continued for up to 12 weeks of amenorrhea at the same doses and then gradually stopped. If the test is negative, HRT will be stopped gradually~Placebo administration:On the day of the first monitoring Dm (corresponding to D13-D16 of the cycle), a single per os dose of placebo (Microcrystalline cellulose) is taken at night, neither the patient nor the investigator knows what drug is the patient getting. Monitoring is systematically performed the next morning.. The treatment will be maintained until the pregnancy test is performed, then if the test is positive, the treatment will be maintained for a total duration of 7 weeks.
Study: NCT05926596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Robotic Exoskeleton
Description: * Participant preparation, placement of wearable sensors and monitoring, and wearable device fitting.~* Lower-limb joint rotations and leg stretching protocol (40-60 minutes). The wearable exoskeleton and its control algorithm are evaluated to rotate leg joints and apply stretching similarly to the forces applied by nurses and caregivers when providing manual forces. Joint rotation and limb stretching is conducted while participants sit down (e.g., in a wheelchair, on a chair, on one side of a bed, or on a clinical mat) or lay down on a bed/mat. The protocol involves ankle plantarflexion and dorsiflexion, knee extension, hip flexion with the knee flexed, and toe flexion and extension (bilaterally) assisted by the exoskeleton, and each movement is repeated at a low-to-moderate rate of 10-30 cycles/minute.~* Treadmilll and Overground Walking (60-90 minutes including rest periods)~* Cool down (5-10 minutes)
Study: NCT06588894

Intervention type: BEHAVIORAL
Intervention: Questionnaire and Physical Exam
Description: Individuals motor imagery skills will be assessed using a mental chronometer and mental rotation, body awareness will be assessed using the Body Awareness Questionnaire, and cognitive functions will be assessed using the Montreal Cognitive Assessment questionnaire.

Intervention type: BEHAVIORAL
Intervention: Motor Imagery Ability
Description: Individuals motor imagery skills will be assessed using a mental stopwatch and mental rotation, body awareness will be assessed using the Body Awareness Questionnaire, and cognitive functions will be assessed using theMontreal Cognitive Assessment questionnaire.
Study: NCT06672718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPY002-091
Description: Experimental

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05275621

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: A Virtual Reality game is provided through a headset. Subjects play in a virtual environment. Positioning of the headset occurs before starting the procedure and is maintained throughout the procedure. The headset used will be Oculus Rift 2 by Facebook Tech. ltd.. The software is designed specifically for the purpose by Softcare Studios. The game played is called Drums.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PICC positioning
Description: A PICC is inserted under ultrasound guidance through a modified Seldinger technique in a deep vein of the upper arm. The skin is infiltrated with 0.5-1ml 2% lidocaine before dilation of the skin. Tip guidance and positioning is achieved through intracavitary ECG.
Study: NCT04946799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-intensity training combined with blood flow restriction (LI-BFR)
Description: Participants (n=20) receives low intensity exercise intervention on a cycle ergometer (at 40% of heart rate reserve), with compression belts attached on both thighs, during exercise the belts are inflated with 50% of the participant's arterial occlusion pressure. Exercise is conducted during daytime, 3 times per week, for 12 weeks at Nanjing Maigaoqiao Community Health Service Center. Each exercise session contains 6 sections, each section lasts for 5 minutes, followed with a 1-minute rest period. The compression belt is deflated during the rest period. At least two trained research assistants supervise the exercise in each session. Instant heart rate during exercise is measured with heart rate monitor for each participant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity aerobic exercise (HI)
Description: Participants (n=20) receives high intensity aerobic exercise intervention on a cycle ergometer (at 70% of heart rate reserve). Exercise is conducted during daytime, 3 times per week, for 12 weeks at Nanjing Maigaoqiao Community Health Service Center. Each exercise session contains 6 sections, each section lasts for 5 minutes, followed with a 1-minute rest period. At least two trained research assistants supervise the exercise in each session. Instant heart rate during exercise is measured with heart rate monitor for each participant.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Low intensity exercise (LI)
Description: Participants (n=20) receives low intensity exercise intervention on a cycle ergometer (at 40% of heart rate reserve). Exercise is conducted during daytime, 3 times per week, for 12 weeks at Nanjing Maigaoqiao Community Health Service Center. Each exercise session contains 6 sections, each section lasts for 5 minutes, followed with a 1-minute rest period. At least two trained research assistants supervise the exercise in each session. Instant heart rate during exercise is measured with heart rate monitor for each participant.
Study: NCT05015010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: 600 mg p.o. (four 150 mg capsules) twice daily with food (within 30 minutes after a meal, in the morning and evening).
Study: NCT06677437

Intervention type: OTHER
Intervention: This is an observational and retrospective study
Description: It concerns all patients with chronic renal failure awaiting a kidney transplant, and presenting a contraindication to the transplant due to their anatomical constraints: major arterial calcifications, iliac dissections, iliac stenoses. They can only receive the kidney transplant after arterial preparation. These patients will be included and will benefit from endovascular preparation for the kidney transplant using a tailor-made arterial stent.~Imaging examinations and follow-up clinical data will be analyzed. Reinterventions and causes of death will be analyzed.~An information sheet will be given to patients; if the patient refuses the use of their data, it will not be collected.~Data collection will be carried out by ARCs or PIs of the centers from medical records. The data will be pseudo-anonymized, entered into a REDCAP database shared between each center.
Study: NCT06677034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Mobile Game-Based Exercise Training
Study: NCT06677073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: High-intensity interval training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maximal fat oxidation exercise
Description: Maximal fat oxidation exercise
Study: NCT06218121

Intervention type: DIAGNOSTIC_TEST
Intervention: Instrumental and Functional Tests that Assess Functional Capacity
Description: The correlation between all functional, ultrasound, nutritional, and psychological variables will be analyzed. Through GLIM diagnosis, anthropometric data (weight, height, BMI) as well as analytical data including inflammation information (CRP and albumin) will be used to reach a diagnosis that allows comparison/correlation with the rest of the variable parameters.
Study: NCT05481359

Intervention type: DEVICE
Intervention: Ablamap Software
Description: Subjects will receive cardiac ablation guided by the Ablamap software. The software will identify atrial fibrillation sources to help guide ablation therapy in patients with persistent atrial fibrillation.
Study: NCT05291650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: The product of the glucocorticoid is betamethasone injectable suspension and the dosage is 1 ml. To alleviate the discomfort on local tissues, the suspension injected into the infrapatellar fat pad will be pre-mixed with 0.5 ml saline and 0.5 ml lidocaine. That is, the total amount of the drug injected into the infrapatellar fat pad for the glucocorticoid group will be 2.0 ml.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: A total of 2.0 ml drug including 1.5 ml saline and 0.5 ml lidocaine will be injected into the infrapatellar fat pad for the placebo group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: After completing the process of infrapatellar fat pad injection, the participants in both groups will receive 2.5 ml hyaluronic acid suspension injection through the suprapatellar bursa into the intra-articular space.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hyaluronic acid
Description: After completing the process of infrapatellar fat pad injection, the participants in both groups will receive 2.5 ml hyaluronic acid suspension injection through the suprapatellar bursa into the intra-articular space.
Study: NCT05973903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Oral Lenvatinib 20 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: intravenous pembrolizumab 200 mg every three weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields (TTFields)
Description: TTF extra-dermal scalp electrodes
Study: NCT06473701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol 2.5mg Capsule
Description: Dronabinol 2.5 mg pr capsule. Titration up till 20 mg daily dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dronabinol 2.5mg Capsule
Description: Dronabinol 2.5 mg pr capsule. Titration up till 20 mg daily dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dronabinol-matched placebo capsule containing no active substance.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dronabinol-matched placebo capsule containing no active substance.
Study: NCT04615819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kidney Transplant Fast Track (KTFT)
Description: Streamlined KT evaluation involving completion of most or all testing on the same day a patient arrives for their first pre-transplant clinic appointment. Or, a transplant clinic scheduler secures testing within a 4 week period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Navigation (PN)
Description: Uses trained, previous KT recipients who meet weekly to monthly with patient participants to provide tailored information and assistance in completing the necessary steps to proceed to transplant.
Study: NCT06474871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Khymeia®-Virtual Reality rehabilitation System (VRRS EVO SYSTEM or COMPACT VRRS ENGINE)
Description: fully immersive VR software created by clinicians and experts specialized in cognitive rehabilitation. Khymeia Devices are Medical Class 1 devices according to MDR. VRRS systems consist of a central process unit, complete with a capacitive touch screen LCD monitor.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional cognitive training (TCT)
Description: face-to-face approach between the therapist and the patient using paper and pencil tools and other traditional materials. The training of the executive abilities is carried out by working on categorization, planning, association processes, analogical reasoning, problem solving and coping strategies to simulate problematic situations, tailored on patients' deficits
Study: NCT05192915

Intervention type: DEVICE
Group type: OTHER
Intervention: Modular customized AFO
Description: Walks better at self selected speed with a modular customized AFO than with a conventional AFO.
Study: NCT05075161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: From days 1-7: 801mg/day; from days 8-14:1602mg/day, from day 15 to ICU discharge 2403 mg/day. All drugs will be delivered by a nasogastric tube divided in 3 daily doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All drugs will be delivered by a nasogastric tube divided in 3 daily doses.
Study: NCT04947722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREVENT Program
Description: A standardized PREVENT educational program will be offered to each intervention LTC home and health-care staff. The curricula includes video modules with fracture-prevention care recommendations and an orientation to the Fracture Prevention Toolkit. Using the Fracture Risk Scale (i.e., a clinical decision support tool embedded in the RAI-MDS 2.0), the LTC team will identify residents at high-risk for fracture and will implement the fracture prevention recommendations into care plans on an individual resident basis.